Advocacy for Women in Orthopaedics
Presented in collaboration with the Ruth Jackson Orthopaedic Society

Chairs: Michelle M. Coleman, MD, PhD (AOFAS) and Lubna Ziauddin (RJOS)

Join a discussion centered on Advocacy for Women in Orthopaedic Surgery. Topics will include recent research examining the challenges faced by female orthopaedic surgeons in the workplace as well as practical strategies for advocating for women in orthopaedics. We will conclude with a discussion panel featuring the Boden family of orthopaedic surgeons.

Reference Texts

• Next Steps: Advocating for Women in Orthopaedic Surgery, by Tamara A. Scerpella, MD; Andrea M. Spiker, MD; Cassandra A. Lee, MD; Mary K. Mulcahey, MD; Molly L. Carnes, MD, MS

• The “Other Side” of Conflict: Examining the Challenges of Female Orthopaedic Surgeons in the Workplace, by Patricia Rodarte, Maria S. Kammire, Lisa K. Cannada, Selina Poon, and Heidi Israel. Conference proceeding from the Medical Student Orthopaedic Symposium 2022.
  
  

  Accreditation

  The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

   

  Credit Designation Statement

  The AOFAS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.

AOFAS requires all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all relevant financial relationships or affiliations during the past 12 months with any commercial interest (any entity producing, marketing, re-selling, or distributing healthcare goods and services consumed by, or used on patients). All identified conflicts of interest must be resolved and the education content vetted by AOFAS for fair balance, scientific objectivity, and appropriateness. AOFAS also requires faculty to disclose when off-label/unapproved uses of a product are discussed in a CME activity. AOFAS attests that the persons responsible for the development of this educational activity did so independently and were not influenced by commercial supporters. All financial disclosures will be provided to meeting attendees in the final program materials.

The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.

FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.

DEI COMMITTEE DISCLOSURES (Faculty and Planners)

Gary W. Stewart, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

J. Robert Gladden Society: Board or committee member

AAOS: Board or committee member

Carbon-22: Stock or Stock Options

Altior: Stock or Stock Options

Novastep: Stock or Stock Options

Tonya Dixon, MD, MPH

American Orthopaedic Foot and Ankle Society: Board or committee member

J. Robert Gladden Society: Board or committee member

Lorena Bejarano-Pineda, MD

This individual reported nothing to disclose

Michelle M. Coleman, MD, PhD

American Orthopaedic Foot and Ankle Society: Board or committee member

J. Imani Dupree, MD

This individual reported nothing to disclose

Robert Gorman III, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

Novastep: Royalties

Arthrex Inc: Speaker’s Bureau/Presenter

Zimmer: Paid Consultant

Novastep: Paid Consultant

Carbon-22: Stock or Stock Options

Altior Trauma: Stock or Stock Options

BICMD: Stock or Stock Options

Anthony Ndu, MD

Tyber Implants: Paid Consultant

Nextremity Solutions: Paid Consultant

Kaitlin Neary, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

Arthrex Inc: Speaker’s Bureau/Presenter

Arthrex Inc: Speaker’s Bureau/Presenter

Arthrex Inc: Research Support

Jacqueline Nguyen, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

David I. Pedowitz, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

Smith & Nephew: Royalties

Zimmer: Royalties

Smith & Nephew: Paid Consultant

Arthrex Inc: Paid Consultant

MiRus: Paid Consultant

Ossio: Paid Consultant

Smith & Nephew: Research Support

Thermaquil: Stock or Stock Options

MiRus: Stock or Stock Options

Arthrex Inc: Speaker’s Bureau/Presenter

Smith & Nephew: Speaker’s Bureau/Presenter

Ossio: Stock or Stock Options

Andres Piscoya, MD

This individual reported nothing to disclose

Vinayak M. Sathe, MD

American Orthopaedic Foot and Ankle Society: Board or committee member

Lubna Ziauddin (RJOS)

This individual reported nothing to disclose